Article

Probability of blindness from glaucoma has nearly halved

The probability of blindness due to glaucoma has decreased by nearly half since 1980, according to a study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology.

 

San Francisco-The probability of blindness due to glaucoma has decreased by nearly half since 1980, according to a study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology.

The researchers-a team based at the Mayo Clinic-speculate that advances in diagnosis and therapy are likely causes for the decrease, but caution that a significant proportion of patients still progress to blindness.

The study was the first to assess long-term changes in the risk of progression to blindness and the population incidence of glaucoma-related blindness. By identifying epidemiologic trends in glaucoma, the researchers hope to gain insight into best practices for the distribution of health and medical resources, as well as management approaches for entire populations.

The researchers reviewed every incident case (857 cases total) of open-angled glaucoma (OAG) diagnosed between 1965 and 2009 in Olmsted County, MN-one of the few places in the world where long-term population-based studies are conducted. They found that the 20-year probability and population incidence of blindness due to OAG in at least one eye had decreased from 25.8% for subjects diagnosed between 1965 and 1980, and to 13.5% for those diagnosed between 1981 and 2000.

The population incidence of blindness within 10 years of diagnosis also decreased from 8.7 per 100,000 to 5.5 per 100,000 for those groups respectively. Yet, 15% of the patients diagnosed in the more recent timeframe still progressed to blindness.

“These results are extremely encouraging for both those suffering from glaucoma and the doctors who care for them, and suggest that the improvements in the diagnosis and treatment have played a key role in improving outcomes,” said Arthur J. Sit, MD, associate professor of ophthalmology at the Mayo Clinic College of Medicine and leader researcher for the study. “Despite this good news, the rate at which people continue to go blind due to OAG is still unacceptably high.

“This is likely due to late diagnosis and our incomplete understanding of glaucoma, so it is critical that research into this devastating disease continues, and all eye-care providers be vigilant in looking for early sighs of glaucoma during routine exams,” he continued.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.